{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:45:10Z","timestamp":1780559110492,"version":"3.54.1"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002224","name":"Melanoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002224","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.bcp.2017.12.019","type":"journal-article","created":{"date-parts":[[2017,12,23]],"date-time":"2017-12-23T21:37:33Z","timestamp":1514065053000},"page":"35-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["The biology and therapeutic management of melanoma brain metastases"],"prefix":"10.1016","volume":"153","author":[{"given":"Daniel","family":"Abate-Daga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Ramello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Smalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiran S.M.","family":"Smalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2017.12.019_b0005","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases","volume":"22","author":"Fife","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2017.12.019_b0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0305-7372(03)00105-1","article-title":"The management of brain metastases","volume":"29","author":"Patchell","year":"2003","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bcp.2017.12.019_b0015","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/107327481302000407","article-title":"Novel treatments for melanoma brain metastases","volume":"20","author":"Kenchappa","year":"2013","journal-title":"Cancer Control"},{"key":"10.1016\/j.bcp.2017.12.019_b0020","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2017.12.019_b0025","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2011.58","article-title":"The biology of brain metastases-translation to new therapies","volume":"8","author":"Eichler","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2017.12.019_b0030","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/COC.0b013e3181f9456a","article-title":"Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma","volume":"34","author":"Bedikian","year":"2011","journal-title":"Am. J. Clin. Oncol.-Canc."},{"key":"10.1016\/j.bcp.2017.12.019_b0035","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1016\/S1470-2045(15)00141-2","article-title":"Evolving treatment options for melanoma brain metastases","volume":"16","author":"Ajithkumar","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2017.12.019_b0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2017.12.019_b0045","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2017.12.019_b0050","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/pcmr.12538","article-title":"Melanoma central nervous system metastases: current approaches, challenges, and opportunities","volume":"29","author":"Cohen","year":"2016","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0055","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2017.12.019_b0060","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1158\/1078-0432.CCR-15-1836","article-title":"Alterations in pericyte subpopulations are associated with elevated blood-tumor barrier permeability in experimental brain metastasis of breast cancer","volume":"22","author":"Lyle","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0065","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1158\/1078-0432.CCR-16-1327","article-title":"Impact of blood-brain barrier integrity on tumor growth and therapy response in brain metastases","volume":"22","author":"Osswald","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0070","first-page":"40","article-title":"Extravascular migration of tumor cells in the brain: an electron microscopic study","volume":"2","author":"Kawaguchi","year":"1982","journal-title":"Invasion Metastasis"},{"key":"10.1016\/j.bcp.2017.12.019_b0075","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/325253a0","article-title":"Astrocytes induce blood-brain barrier properties in endothelial cells","volume":"325","author":"Janzer","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.12.019_b0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/(SICI)1098-1136(199701)19:1<13::AID-GLIA2>3.0.CO;2-B","article-title":"Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes","volume":"19","author":"Hayashi","year":"1997","journal-title":"Glia"},{"key":"10.1016\/j.bcp.2017.12.019_b0085","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1073\/pnas.0805165106","article-title":"Wnt\/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis","volume":"106","author":"Daneman","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.bcp.2017.12.019_b0090","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature09522","article-title":"Pericytes regulate the blood-brain barrier","volume":"468","author":"Armulik","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.12.019_b0095","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/nn.2946","article-title":"Central nervous system pericytes in health and disease","volume":"14","author":"Winkler","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bcp.2017.12.019_b0100","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","article-title":"Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer","volume":"16","author":"Lockman","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nm.2072","article-title":"Real-time imaging reveals the single steps of brain metastasis formation","volume":"16","author":"Kienast","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2017.12.019_b0110","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.2353\/ajpath.2010.090838","article-title":"Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis","volume":"176","author":"Lorger","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcp.2017.12.019_b0115","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/path.4304","article-title":"Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain","volume":"232","author":"Avraham","year":"2014","journal-title":"J. Pathol."},{"key":"10.1016\/j.bcp.2017.12.019_b0120","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/ncb3011","article-title":"Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S","volume":"16","author":"Sevenich","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bcp.2017.12.019_b0125","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1091\/mbc.12.9.2699","article-title":"Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells","volume":"12","author":"Voura","year":"2001","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bcp.2017.12.019_b0130","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10585-005-8115-6","article-title":"Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model","volume":"22","author":"Mendes","year":"2005","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.bcp.2017.12.019_b0135","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1215\/S115285170300067X","article-title":"Brain metastases in melanoma: roles of neurotrophins","volume":"6","author":"Denkins","year":"2004","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bcp.2017.12.019_b0140","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/mrm.21029","article-title":"In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain","volume":"56","author":"Heyn","year":"2006","journal-title":"Magn. Reson. Med."},{"key":"10.1016\/j.bcp.2017.12.019_b0145","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.cell.2014.01.040","article-title":"Serpins promote cancer cell survival and vascular co-option in brain metastasis","volume":"156","author":"Valiente","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2017.12.019_b0150","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3892\/ijo_00000378","article-title":"Generation of an immortalized astrocyte cell line from H-2Kb-tsA58 mice to study the role of astrocytes in brain metastasis","volume":"35","author":"Langley","year":"2009","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bcp.2017.12.019_b0155","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13277-015-4242-0","article-title":"The role of astrocytes in the progression of brain cancer: complicating the picture of the tumor microenvironment","volume":"37","author":"Placone","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.bcp.2017.12.019_b0160","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/emmm.201201623","article-title":"Reactive astrocytes promote the metastatic growth of breast cancer stem-like cells by activating Notch signalling in brain","volume":"5","author":"Xing","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bcp.2017.12.019_b0165","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s10585-008-9193-z","article-title":"Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization","volume":"25","author":"Fitzgerald","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.bcp.2017.12.019_b0170","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1593\/neo.11112","article-title":"Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy","volume":"13","author":"Kim","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.bcp.2017.12.019_b0175","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1593\/neo.10602","article-title":"Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels","volume":"12","author":"Lin","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.bcp.2017.12.019_b0180","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/glia.21022","article-title":"Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way","volume":"58","author":"Pukrop","year":"2010","journal-title":"Glia"},{"key":"10.1016\/j.bcp.2017.12.019_b0185","doi-asserted-by":"crossref","first-page":"e80933","DOI":"10.1371\/journal.pone.0080933","article-title":"Astrocytes directly influence tumor cell invasion and metastasis in vivo","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2017.12.019_b0190","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10585-009-9238-y","article-title":"Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model","volume":"26","author":"JuanYin","year":"2009","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.bcp.2017.12.019_b0195","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00401-009-0619-8","article-title":"Astrocytes: biology and pathology","volume":"119","author":"Sofroniew","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bcp.2017.12.019_b0200","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nature18268","article-title":"Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer","volume":"533","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.12.019_b0205","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.ajpath.2013.02.043","article-title":"Pazopanib inhibits the activation of PDGFRbeta-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells","volume":"182","author":"Gril","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcp.2017.12.019_b0210","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature15376","article-title":"Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth","volume":"527","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.12.019_b0215","doi-asserted-by":"crossref","first-page":"82","DOI":"10.18632\/oncoscience.11","article-title":"Melanoma brain colonization involves the emergence of a brain-adaptive phenotype","volume":"1","author":"Nygaard","year":"2014","journal-title":"Oncoscience"},{"key":"10.1016\/j.bcp.2017.12.019_b0220","doi-asserted-by":"crossref","first-page":"17456","DOI":"10.1073\/pnas.1114210108","article-title":"Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis","volume":"108","author":"Park","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.bcp.2017.12.019_b0225","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.tcb.2013.07.007","article-title":"Oligodendroglia: metabolic supporters of axons","volume":"23","author":"Morrison","year":"2013","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bcp.2017.12.019_b0230","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/jbiol50","article-title":"CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo","volume":"5","author":"Dietrich","year":"2006","journal-title":"J. Biol."},{"key":"10.1016\/j.bcp.2017.12.019_b0235","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1158\/1078-0432.CCR-09-1985","article-title":"Integrated molecular and clinical analysis of AKT activation in metastatic melanoma","volume":"15","author":"Davies","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0240","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cam4.50","article-title":"Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases","volume":"2","author":"Niessner","year":"2013","journal-title":"Cancer Med."},{"key":"10.1016\/j.bcp.2017.12.019_b0245","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-13-3003","article-title":"Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target","volume":"20","author":"Chen","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0250","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.celrep.2015.09.057","article-title":"AKT1 activation promotes development of melanoma metastases","volume":"13","author":"Cho","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2017.12.019_b0255","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1158\/1078-0432.CCR-14-1027","article-title":"Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB\/C melanoma patients with BRAFV600 mutations","volume":"20","author":"Bucheit","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0260","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1158\/1078-0432.CCR-14-0861","article-title":"PLEKHA5 as a biomarker and potential mediator of melanoma brain metastasis","volume":"21","author":"Jilaveanu","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0265","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bcp.2017.12.019_b0270","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41467-017-00196-1","article-title":"Molecular characterization of breast cancer CTCs associated with brain metastasis","volume":"8","author":"Boral","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2017.12.019_b0275","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1158\/0008-5472.CAN-05-2674","article-title":"Activation of Stat3 in human melanoma promotes brain metastasis","volume":"66","author":"Xie","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0280","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1158\/0008-5472.CAN-12-2194","article-title":"Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma","volume":"72","author":"Cruz-Munoz","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0285","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S1044-7431(03)00068-X","article-title":"Neurons and astrocytes secrete factors that cause stem cells to differentiate into neurons and astrocytes, respectively","volume":"23","author":"Chang","year":"2003","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.bcp.2017.12.019_b0290","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1126\/science.283.5401.496","article-title":"Energy on demand","volume":"283","author":"Magistretti","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bcp.2017.12.019_b0295","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.neuint.2003.08.014","article-title":"Cerebral glucose metabolism and the glutamine cycle as detected by in vivo and in vitro 13C NMR spectroscopy","volume":"45","author":"Garcia-Espinosa","year":"2004","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bcp.2017.12.019_b0300","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/0008-5472.CAN-06-3137","article-title":"Adaptation of energy metabolism in breast cancer brain metastases","volume":"67","author":"Chen","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0305","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/0008-5472.CAN-14-2268","article-title":"Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain","volume":"75","author":"Chen","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0310","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.12.019_b0315","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bcp.2011.05.015","article-title":"Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma","volume":"82","author":"Fedorenko","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2017.12.019_b0320","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ccr.2010.10.029","article-title":"Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A","volume":"19","author":"Arozarena","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2017.12.019_b0325","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1158\/0008-5472.CAN-10-2954","article-title":"PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression","volume":"71","author":"Paraiso","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0330","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.12.019_b0335","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.12.019_b0340","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2017.12.019_b0345","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccr.2012.10.009","article-title":"Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas","volume":"22","author":"Lito","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2017.12.019_b0350","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2017.12.019_b0355","doi-asserted-by":"crossref","DOI":"10.1097\/CMR.0000000000000338","article-title":"Does the distribution of pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching","author":"Haueis","year":"2017","journal-title":"Melanoma Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0360","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/pcmr.12424","article-title":"Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases","volume":"29","author":"Seifert","year":"2016","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0365","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1200\/JCO.2016.67.2410","article-title":"Management of brain metastases in ALK-positive non-small-cell lung cancer","volume":"34","author":"Rusthoven","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2017.12.019_b0370","doi-asserted-by":"crossref","first-page":"563","DOI":"10.21037\/tlcr.2016.10.16","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future","volume":"5","author":"Proto","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0375","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/jpet.112.192195","article-title":"Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)","volume":"342","author":"Mittapalli","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2017.12.019_b0380","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/jpet.112.201475","article-title":"Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases","volume":"344","author":"Mittapalli","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2017.12.019_b0385","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/cncr.28445","article-title":"Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib","volume":"120","author":"Azer","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2017.12.019_b0390","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2006.10.0677","article-title":"Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm","volume":"25","author":"Gerstner","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2017.12.019_b0395","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2017.12.019_b0400","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/CMR.0000000000000162","article-title":"Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma","volume":"25","author":"Sakji-Dupre","year":"2015","journal-title":"Melanoma Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0405","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2017.12.019_b0410","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2017.12.019_b0415","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-16-0064","article-title":"PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo","volume":"22","author":"Niessner","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0420","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal4682","article-title":"The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation","volume":"9","author":"Kodack","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2017.12.019_b0425","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nrc2246","article-title":"Making a tumour's bed: glioblastoma stem cells and the vascular niche","volume":"7","author":"Gilbertson","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2017.12.019_b0430","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nature07567","article-title":"Efficient tumour formation by single human melanoma cells","volume":"456","author":"Quintana","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2017.12.019_b0435","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.19671","article-title":"Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors","volume":"6","author":"Mulcahy Levy","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.bcp.2017.12.019_b0440","first-page":"1","article-title":"Astrocytes promote progression of breast cancer metastases to the brain via a KISS1-mediated autophagy","author":"Kaverina","year":"2017","journal-title":"Autophagy"},{"key":"10.1016\/j.bcp.2017.12.019_b0445","doi-asserted-by":"crossref","first-page":"e1057388","DOI":"10.1080\/2162402X.2015.1057388","article-title":"Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases","volume":"5","author":"Berghoff","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bcp.2017.12.019_b0450","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/cas.13101","article-title":"Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients","volume":"107","author":"Ogiya","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2017.12.019_b0455","doi-asserted-by":"crossref","first-page":"8228","DOI":"10.1158\/1078-0432.CCR-08-1329","article-title":"The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas","volume":"14","author":"Abou-Ghazal","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0460","doi-asserted-by":"crossref","first-page":"385","DOI":"10.21037\/atm.2017.06.11","article-title":"Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy","volume":"5","author":"Zuazo","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.bcp.2017.12.019_b0465","article-title":"Emerging targets in cancer immunotherapy","author":"Burugu","year":"2017","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2017.12.019_b0470","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.coi.2017.07.014","article-title":"Lessons from CTLA-4 deficiency and checkpoint inhibition","volume":"49","author":"Lo","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bcp.2017.12.019_b0475","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/CMR.0b013e3283364a37","article-title":"Complete regression of a previously untreated melanoma brain metastasis with ipilimumab","volume":"20","author":"Schartz","year":"2010","journal-title":"Melanoma Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0480","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2017.12.019_b0485","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/CMR.0b013e32834d3d88","article-title":"Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial","volume":"21","author":"Weber","year":"2011","journal-title":"Melanoma Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0490","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cam4.140","article-title":"Ipilimumab and radiation therapy for melanoma brain metastases","volume":"2","author":"Silk","year":"2013","journal-title":"Cancer Med."},{"key":"10.1016\/j.bcp.2017.12.019_b0495","doi-asserted-by":"crossref","first-page":"e28780","DOI":"10.4161\/onci.28780","article-title":"Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy","volume":"3","author":"Grimaldi","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bcp.2017.12.019_b0500","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2017.12.019_b0505","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/1078-0432.CCR-14-3073","article-title":"Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites","volume":"21","author":"Kluger","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0510","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40425-017-0282-x","article-title":"Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment","volume":"5","author":"Anderson","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2017.12.019_b0515","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9507","article-title":"Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204","volume":"35","author":"Tawbi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2017.12.019_b0520","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9508","article-title":"A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): the anti-PD1 brain collaboration (ABC)","volume":"35","author":"Long","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2017.12.019_b0525","article-title":"Immunotherapy: tisagenlecleucel \u2013 the first approved CAR-T-cell therapy: implications for payers and policy makers","author":"Prasad","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2017.12.019_b0530","unstructured":"FDA Approves Second CAR T-cell Therapy. Cancer Discov 2017."},{"key":"10.1016\/j.bcp.2017.12.019_b0535","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/mto.2016.14","article-title":"CAR models: next-generation CAR modifications for enhanced T-cell function","volume":"3","author":"Abate-Daga","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.bcp.2017.12.019_b0540","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/imr.12132","article-title":"Exploiting the curative potential of adoptive T-cell therapy for cancer","volume":"257","author":"Hinrichs","year":"2014","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bcp.2017.12.019_b0545","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2017.12.019_b0550","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1158\/1078-0432.CCR-10-1507","article-title":"Successful treatment of melanoma brain metastases with adoptive cell therapy","volume":"16","author":"Hong","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2017.12.019_b0555","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3171\/2011.3.JNS091107","article-title":"Surgical management of melanoma brain metastases in patients treated with immunotherapy","volume":"115","author":"Lonser","year":"2011","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.bcp.2017.12.019_b0560","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2017.12.019_b0565","article-title":"Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies","author":"Sloot","year":"2017","journal-title":"Cancer"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217307311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217307311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:06:21Z","timestamp":1757768781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295217307311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":113,"alternative-id":["S0006295217307311"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2017.12.019","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The biology and therapeutic management of melanoma brain metastases","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2017.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}